RT Journal Article
SR Electronic
T1 Estimating seroprevalence of SARS-CoV-2 infection after a highly contagious Omicron outbreak: A cross sectional study in a university setting
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.29.23293775
DO 10.1101/2023.08.29.23293775
A1 Hou, Ching-Wen
A1 Williams, Stacy
A1 Trivino-Soto, Guillermo
A1 Boyle, Veronica
A1 Rainford, David
A1 Vicino, Selina
A1 Magee, Mitch
A1 Chung, Yunro
A1 LaBaer, Joshua
A1 Murugan, Vel
YR 2023
UL http://medrxiv.org/content/early/2023/08/29/2023.08.29.23293775.abstract
AB Objective This study aimed to investigate the seroprevalence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibodies among individuals aged 18 years and olderDesign Prospective cohort study.Settings Population-based study was conducted within the Arizona State University (ASU) community.Participants The study recruited 1,397 adult participants that volunteered over a period of three days (March 1-March 3 of 2022).Primary outcome measures Seroprevalence was conducted in the community to assess the presence of SARS-CoV-2-specific antibodies resulting from previous exposure to SARS-CoV-2 and/or vaccination.Results The seroprevalence of anti-receptor binding domain (RBD) antibodies was found to be 96.3% using a semi-quantitative chemiluminescent immunoassay and 98% using an electrochemiluminescent immunoassay. For anti-nucleocapsid (NC) antibodies, the seroprevalence was 39.1% by an ELISA assay and 41.4% by an electrochemiluminescent immunoassay. Individuals that experienced breakthrough infections exhibited the highest levels of anti-RBD antibodies. Additionally, saliva samples showed promise as a potential diagnostic biofluid for measuring antibody levels, as they exhibited a strong correlation with the data obtained from serum samples.Conclusion Accurate estimation of population-based serosurveillance for SARS-CoV- 2 will monitor the trend of infection in the community and delineate the geographical spread of the infection. Cumulative incidence of SARS-CoV-2 infection during and after outbreaks is crucial for informing the development of effective risk mitigation protocols within the community. Protocols may include measures such as encouraging booster shots, extending mask mandates, or transitioning to online classes. Serosurveys repeated at regular intervals can also guide containment measures in communities and prompt response to future outbreaks.Strengths and limitations of this studyWe simultaneously investigated active infection and seroprevalence for the university population.Our study was strengthened by having the participants’ self-report data independently validated with diagnostic tests.Saliva samples could be a potential diagnostic biofluid for measuring antibody levels.Our study was performed within the university setting therefore it only reflects the COVID-19 situation within that community.The number of breakthrough infections and the longitudinal samples were small, thus requiring confirmation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Arizona State University Knowledge Enterprise.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Arizona State University Institutional Review Board gave approval for this study. Study ID: STUDY00015522I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors